Ptc Therapeutics (PTCT) Debt to Equity (2016 - 2025)
Ptc Therapeutics has reported Debt to Equity over the past 14 years, most recently at -$1.4 for Q4 2025.
- Quarterly results put Debt to Equity at -$1.4 for Q4 2025, down 182.2% from a year ago — trailing twelve months through Dec 2025 was -$1.4 (down 182.2% YoY), and the annual figure for FY2025 was -$1.4, down 182.2%.
- Debt to Equity for Q4 2025 was -$1.4 at Ptc Therapeutics, up from -$1.84 in the prior quarter.
- Over the last five years, Debt to Equity for PTCT hit a ceiling of $237.26 in Q4 2021 and a floor of -$3.89 in Q1 2022.
- Median Debt to Equity over the past 5 years was -$1.09 (2023), compared with a mean of $11.0.
- Biggest five-year swings in Debt to Equity: soared 34535.93% in 2021 and later tumbled 402.23% in 2025.
- Ptc Therapeutics' Debt to Equity stood at $237.26 in 2021, then plummeted by 100.78% to -$1.86 in 2022, then surged by 68.49% to -$0.58 in 2023, then rose by 15.38% to -$0.49 in 2024, then tumbled by 182.2% to -$1.4 in 2025.
- The last three reported values for Debt to Equity were -$1.4 (Q4 2025), -$1.84 (Q3 2025), and -$2.65 (Q2 2025) per Business Quant data.